Research Progress of Thalidomide and Its Derivatives in Treatment of Myelodysplastic Syndrome--Review.
10.19746/j.cnki.issn.1009-2137.2021.06.048
- Author:
Jing-Wen WANG YIN
1
;
Gao-Feng JIANG
2
;
Jian NI
3
;
Yong-Ming ZHOU
4
Author Information
1. Department of Hematology,Tianyou Hospital Affiliated to Wuhan University of Science and Technology, Wuhan 430000, Hubei Province, China.
2. Translational Medicine Center,Tianyou Hospital Affiliated to Wuhan University of Science and Technology, Wuhan 430000, Hubei Province, China.
3. Department of Onology Clinical Pharmacy, Brigham and Women's Hospital, Harvard Medical School, Boston MA02115, USA E-mail: Jni2@bwh.harvard.edu.
4. Department of Hematology,Tianyou Hospital Affiliated to Wuhan University of Science and Technology, Wuhan 430000, Hubei Province, China E-mail: zhym112@126.com.
- Publication Type:Review
- MeSH:
Humans;
Immunomodulating Agents;
Myelodysplastic Syndromes/drug therapy*;
Thalidomide/therapeutic use*
- From:
Journal of Experimental Hematology
2021;29(6):1967-1971
- CountryChina
- Language:Chinese
-
Abstract:
Thalidomide and its derivatives have been used in the treatment of myelodysplastic syndrome (MDS) because of their anti-angiogenic and immunomodulatory effects. In recent years, some studies have found that thalidomide and its derivatives not only showed significant efficacy in lower-risk MDS patients with del (5q), but also showed advantages in non-del (5q) MDS patients. In addition, the discovery of its molecular targets and new substrates makes it possible to develop a new generation of immunomodulatory drugs (IMiDs) and to design IMiDs-based proteolysis-targeting chimeras. In this review, the new progress in mechanism and clinical application of thalidomide and its derivatives were summarized briefly, so as to provide a more scientific, reasonable and effective scheme to the treatment of MDS.
